Pretreatment of colon carcinoma cells with tomudex enhances 5- fluorouracil cytotoxicity

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 469-473

  Longo, Giuseppe S A ^a   Izzo, Julie ^a,b   Chang, Yu Ming ^a   Tong, William P ^a   Zielinski, Zbigniev ^a,c   Gorlick, Richard ^a   Chou, Ting Chao ^a   Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; RALTITREXED;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; CELL KILLING; CLONOGENIC ASSAY; COLON CARCINOMA; CONTINUOUS INFUSION; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PURINE SYNTHESIS; RNA METABOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FLUOROURACIL; HUMANS; NUCLEOTIDES; PHOSPHORIBOSYL PYROPHOSPHATE; QUINAZOLINES; RNA, NEOPLASM; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0031937913     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sobrero, A. F., Aschele, C., and Bertino, J. R. Fluorouracil in colorectal cancer-a tale of two drugs: implication for biochemical modulation. J. Clin. Oncol., 15: 368-381, 1997.
2. Rustum, Y. M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M-B., Wilke, H., and Seeber, S. Thymidylate synthetase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol., 15: 389-400, 1997.
3. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvett, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthetase inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
4. Zalcberg, J. R., Cunningham, D., Van Cutsem, E., Francois, E., Schornagel, J., Adenis, A., Green, M., Iveson, A., Azab, M., and Seymour, I. D1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex colorectal study group. J. Clin. Oncol., 14: 716-721, 1996.
5. Aschele, C., Sobrero, A., Faderan, M. A., and Bertino, J. R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines. Cancer Res., 52: 1855-1864, 1992.
6. Fernandes, D. J., and Bertino, J. R. 5-Fluorouracil-methotrexate synergy. Enhancement of 5-fluorodeoxyuridine binding to thymidylate synthetase by dihydropteroylpolyglutamates. Proc. Natl. Acad. Sci. USA, 77: 5663-5667, 1980.
7. Pogolotti, A. L., Jr., Nolan, P. A., and Santi, D. V. Method for the complete analysis of 5-fluorouracil metabolites in cell extracts. Anal. Biochem., 117: 178-181, 1981.
8. King, M. T., Passoneau, J. U., and Veech, R. L. Radiometric measurement of phosphoribosylpyrophosphate and ribose 5-phosphate by enzymatic procedures. Anal. Biochem., 187: 179-186, 1990.
9. Yalowich, J. C., and Kalman, T. I. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem. Pharmacol., 34: 2319-2324, 1985.
10. Rodenhuis, S., McGuire, J. J., Narayanan, R., and Bertino, J. R. Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res., 46: 6513-6519, 1986.
11. Seifert, P., Baker, L. H., Reed, M. L., and Vaitkevicius, V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer (Phila.), 36: 123-128, 1975.
12. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1983.
13. Sobrero, A., Romanini, A., Russello, O., Nicolin, A., Rosso, R., and Bertino, J. R. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction. Eur. J. Cancer Clin. Oncol., 25: 977-982, 1989.
14. Conti, J. A., Kemeny, N., Seutzer, K., Goker, E., Tong, W., Andre, M., Ragusa, K., and Bertino, J. R. Trial of sequential trimetrxate, fluorouracil, and high dose leucovorin in previously treated patients with gastrointestinal carcinoma. J. Clin. Oncol., 12: 695-700, 1994.
15. Cadman, E., Heimer, R., and Davis, L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science (Washington DC), 205: 1135-1137, 1979.
16. Webber, S., Bartlett, C. A., Boritzki, T. J., Hillard, J. A., Howland, E. F., Johnston, A. L., Kosa, M., Margosiak, S. A., Morse, C. A., and Shetty, B. V. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol., 37: 509-517, 1996.